Table 1.
Clinical, hemodynamic, and ergospirometric characteristic of study population
| Patients, n | 144 |
| Age (years) | 53 ± 16 |
| Gender, M/F | 61/82 |
| PAH etiology, n (%) | |
| Idiopathic PAH | 126 (87.5) |
| Hereditary PAH | 3 (2.1) |
| PAH associated to connective tissue disease | 10 (6.9) |
| Portopulmonary PAH | 4 (2.8) |
| PAH associated to HIV infection | 1 (0.7) |
| WHO, class | |
| I, n (%) | 2 (1.4) |
| II, n (%) | 45 (31.3) |
| III, n (%) | 93 (64.5) |
| IV, n (%) | 4 (2.8) |
| Hemodynamic parameters | |
| mPAP (mmHg) | 45 ± 15 |
| CI (l/min/m2) | 2.5 ± 0.7 |
| RAP (mmHg) | 7.5 ± 3.9 |
| PVR (WU) | 9.1 ± 5.5 |
| Ergospirometric parameters | |
| AT workload (watt) | 39 ± 22 |
| Peak workload (watt) | 68 ± 32 |
| AT HR (b/min) | 108 ± 18 |
| Peak HR (b/min) | 131 ± 24 |
| AT VO2 (ml/kg/min) | 11.2 ± 3.4 |
| Peak VO2 (ml/kg/min) | 15.5 ± 4.7 |
| Peak VO2 (% predicted) | 59 ± 19 |
| Peak O2 pulse (ml) | 8.8 ± 3.4 |
| Peak PETCO2 (mmHg) | 25.9 ± 6.1 |
| VE/VCO2 slope | 45.5 ± 14.4 |
| VO2/work slope | 9.7 ± 2.8 |
Note: Data are expressed as absolute numbers and percentages or mean ± SD. AT is not measurable in 18 patients.
Abbreviations: AT, anaerobic threshold; CI, cardiac index; HIV, human immunodeficiency virus; HR, heart rate; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PETCO2, end‐tidal carbon dioxide pressure; pulse O2, oxygen pulse; PVR, pulmonary vascular resistance; RAP, right atrial pressure; VO2, oxygen uptake; VE/VCO2 slope, ventilation to carbon dioxide production slope; VO2/work: oxygen uptake to work slope; WHO, World Health Organization.